Physician profile
Deidre Stelly
NPI 1144218868
$1,965.75
in general payments reported to CMS, 2019-2025
23 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2021: $111 · 2022: $394 · 2023: $418 · 2024: $229 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339.05 | 2023-2025 | Evenity, Prolia, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.77 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $194.39 | 2022 | |
| Glaxosmithkline, LLC. | $187.52 | 2019-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $125.00 | 2025 | Ozempic |
| Pfizer INC. | $124.56 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $93.94 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $84.53 | 2019 | |
| Organon LLC | $78.21 | 2021-2025 | Nexplanon |
| Janssen Biotech, INC. | $68.04 | 2025 | Tremfya, Simponi Aria |
| Exact Sciences Corporation | $53.72 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $52.55 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $49.29 | 2022-2024 | Xarelto |
| Global Blood Therapeutics, INC. | $36.71 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.97 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.27 | 2023-2024 | |
| Dynavax Technologies Corporation | $31.53 | 2022-2025 | Heplisav-B |
| Lundbeck LLC | $27.77 | 2025 | Rexulti |
| Sun Pharmaceutical Industries INC. | $27.49 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.28 | 2022 | |
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $12.16 | 2022 | |
| Eisai INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deidre Stelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.